Related Experiment Video
Updated: Aug 16, 2025

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
The Activity of Polyhomoarginine against Acanthamoeba castellanii
Hari Kumar Peguda1, Rajamani Lakshminarayanan2,3,4, Nicole A Carnt1
1School of Optometry and Vision Science, University of New South Wales, Sydney 2052, Australia.
Abstract:
Arginine-rich peptides can have broad-spectrum anti-bacterial and anti-fungal activities. Polyhomoarginine consists of highly cationic residues which can act on the negatively charged microbial cell membranes. Acanthamoeba is a free-living protozoan known to cause a rare corneal infection which is difficult to diagnose and treat. This study evaluated the activity of the polyhomoarginines against Acanthamoeba castellanii. Acanthamoeba amoebicidal, amoebistatic, encystation and excystment assays were performed using protocols described in the literature. The activity of polyhomoarginines (PHAs) of different lengths (10 to 400 residues) was measured against the trophozoites and cysts of Acanthamoeba castellanii ATCC30868 in concentrations ranging from 0.93 μM to 15 μM. Data were represented as mean ± SE and analysed using one-way ANOVA. Overall, PHAs demonstrated good anti-acanthamoeba activity against both trophozoites and cysts. PHA 30 reduced the number of viable trophozoites by 99%, inhibited the formation of cysts by 96% and the emergence of trophozoites from cysts by 67% at 3.75 μM. PHA 10 was similarly active, but at a slightly higher concentration of 15 μM, reducing the numbers of viable trophozoites by 98%, inhibiting cyst formation by 84% and preventing the emergence of trophozoites from cysts by 99%. At their greatest anti-amoeba concentrations, PHA 10 gave only 8% haemolysis at 15 μM while PHA 30 gave <40 % haemolysis at 3.75 μM. Polyhomoarginine 10 showed excellent anti-amoebic activity against both forms of Acanthamoeba castellanii and was non-toxic at its most active concentrations. This implies that polyhomoarginines can be developed into a potential therapeutic agent for Acanthamoeba keratitis. However, there is a need to carry out further pre-clinical and then in vivo experiments in the AK animal model.
Insights
Polyhomoarginines (PHAs) show potent anti-amoeba activity against Acanthamoeba castellanii, inhibiting both trophozoites and cysts. PHA 10 demonstrated excellent efficacy and low toxicity, suggesting potential for treating Acanthamoeba keratitis.
Area of Science:
- Microbiology
- Parasitology
- Biochemistry
Background:
- Arginine-rich peptides exhibit broad-spectrum antimicrobial properties.
- Polyhomoarginines (PHAs) possess highly cationic residues effective against microbial cell membranes.
- Acanthamoeba castellanii causes difficult-to-treat Acanthamoeba keratitis.
Purpose of the Study:
- To evaluate the anti-amoeba activity of polyhomoarginines (PHAs) against Acanthamoeba castellanii.
- To assess the efficacy of PHAs against both trophozoite and cyst forms of Acanthamoeba.
- To determine the safety profile of PHAs concerning host cell toxicity.
Main Methods:
- Acanthamoeba amoebicidal, amoebistatic, encystation, and excystment assays were conducted.
- Polyhomoarginines of varying lengths (10-400 residues) were tested at concentrations from 0.93 μM to 15 μM.
- Data analysis involved one-way ANOVA, with haemolysis assays for toxicity assessment.
Main Results:
- PHAs demonstrated significant anti-acanthamoeba activity against both trophozoites and cysts.
- PHA 30 (3.75 μM) reduced trophozoites by 99%, inhibited cyst formation by 96%, and excystment by 67%.
- PHA 10 (15 μM) showed comparable activity, reducing trophozoites by 98%, inhibiting cyst formation by 84%, and excystment by 99% with minimal haemolysis.
Conclusions:
- Polyhomoarginine 10 exhibits excellent anti-amoebic activity and low toxicity against Acanthamoeba castellanii.
- PHAs show promise as a potential therapeutic agent for Acanthamoeba keratitis.
- Further pre-clinical and in vivo studies are warranted to validate therapeutic potential.
More Related Videos
07:33Author Spotlight: Studying Behavior of Acanthamoeba to Develop Targeted Strategies for Preventing Acanthamoeba Keratitis
Published on: September 20, 2024
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016